229 related articles for article (PubMed ID: 32505231)
21.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
22. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
[TBL] [Abstract][Full Text] [Related]
23. MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?
Cosentino F; Viale P; Giannella M
Curr Opin Infect Dis; 2023 Dec; 36(6):564-571. PubMed ID: 37930070
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group.
Averbuch D; Tridello G; Hoek J; Mikulska M; Akan H; Yanez San Segundo L; Pabst T; Özçelik T; Klyasova G; Donnini I; Wu D; Gülbas Z; Zuckerman T; Botelho de Sousa A; Beguin Y; Xhaard A; Bachy E; Ljungman P; de la Camara R; Rascon J; Ruiz Camps I; Vitek A; Patriarca F; Cudillo L; Vrhovac R; Shaw PJ; Wolfs T; O'Brien T; Avni B; Silling G; Al Sabty F; Graphakos S; Sankelo M; Sengeloev H; Pillai S; Matthes S; Melanthiou F; Iacobelli S; Styczynski J; Engelhard D; Cesaro S
Clin Infect Dis; 2017 Nov; 65(11):1819-1828. PubMed ID: 29020364
[TBL] [Abstract][Full Text] [Related]
25. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
[TBL] [Abstract][Full Text] [Related]
26. Direct medical costs of urinary tract infections by Gram-negative bacilli resistant to beta-lactams in a tertiary care hospital in Medellín, Colombia.
Vargas-Alzate CA; Higuita-Gutiérrez LF; Jiménez-Quiceno JN
Biomedica; 2019 May; 39(s1):35-49. PubMed ID: 31529847
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.
Strich JR; Ricotta E; Warner S; Lai YL; Demirkale CY; Hohmann SF; Rhee C; Klompas M; Palmore T; Powers JH; Dekker JP; Adjemian J; Matsouaka R; Woods CW; Danner RL; Kadri SS
Clin Infect Dis; 2021 Feb; 72(4):611-621. PubMed ID: 32107536
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
Jacquier H; Le Monnier A; Carbonnelle E; Corvec S; Illiaquer M; Bille E; Zahar JR; Jauréguy F; Fihman V; Tankovic J; Cattoir V;
Microb Drug Resist; 2012 Aug; 18(4):396-401. PubMed ID: 22335615
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
[TBL] [Abstract][Full Text] [Related]
31. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
33. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
McGowan JE
Am J Med; 2006 Jun; 119(6 Suppl 1):S29-36; discussion S62-70. PubMed ID: 16735148
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
35. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
36. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
37. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).
Mathai D; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Jul; 40(3):129-36. PubMed ID: 11502382
[TBL] [Abstract][Full Text] [Related]
39. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014.
Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
BMC Infect Dis; 2020 Apr; 20(1):269. PubMed ID: 32264851
[TBL] [Abstract][Full Text] [Related]
40. A Decision Tree Using Patient Characteristics to Predict Resistance to Commonly Used Broad-Spectrum Antibiotics in Children With Gram-Negative Bloodstream Infections.
Sick-Samuels AC; Goodman KE; Rapsinski G; Colantouni E; Milstone AM; Nowalk AJ; Tamma PD
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):142-149. PubMed ID: 30690525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
